A. Kakafika

发表

The Effect of Apolipoprotein E Polymorphism on the Response to Lipid-Lowering Treatment With Atorvastatin or Fenofibrate

D. Mikhailidis, E. Liberopoulos, M. Elisaf, 2006, Journal of cardiovascular pharmacology and therapeutics.

Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients

D. Mikhailidis, V. Athyros, A. Karagiannis, 2007, Lipids.

Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Expert opinion on investigational drugs.

Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures.

D. Mikhailidis, K. Paraskevas, V. Athyros, 2007, Current drug targets.

Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort

D. Mikhailidis, E. Liberopoulos, M. Elisaf, 2007, Angiology.

The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity Published, JLR Papers in Press, July 16, 2003. DOI 10.1194/jlr.M300129-JLR200

M. Elisaf, R. Kalaitzidis, A. Tambaki, 2003, Journal of Lipid Research.

CORONA, Statins, and Heart Failure: Who Lost the Crown?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Angiology.

Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2007, Expert opinion on pharmacotherapy.

Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients§

D. Mikhailidis, M. Elisaf, V. Athyros, 2007, The open cardiovascular medicine journal.

Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study.

D. Mikhailidis, M. Elisaf, V. Athyros, 2005, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study

S. Daskalopoulou, D. Mikhailidis, M. Elisaf, 2004, Current medical research and opinion.

Adrenal incidentaloma: a diagnostic challenge

D. Mikhailidis, V. Athyros, A. Karagiannis, 2009, Hormones.

PCI and stable coronary heart disease--COURAGE to change our minds?

D. Mikhailidis, A. Wierzbicki, V. Athyros, 2007, Current vascular pharmacology.

Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Expert opinion on pharmacotherapy.

Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.

H. Milionis, M. Elisaf, E. Bairaktari, 2004, American heart journal.

Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, The American journal of cardiology.

Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study

D. Mikhailidis, K. Paraskevas, V. Athyros, 2008, Current medical research and opinion.

Dyslipidaemia, hypercoagulability and the metabolic syndrome.

D. Mikhailidis, V. Athyros, E. Liberopoulos, 2006, Current vascular pharmacology.

Comparative Effects of Atorvastatin, Simvastatin, and Fenofibrate on Serum Homocysteine Levels in Patients with Primary Hyperlipidemia

H. Milionis, M. Elisaf, K. Seferiadis, 2003, Journal of clinical pharmacology.

Pleiotropic effects of statins--clinical evidence.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2009, Current pharmaceutical design.

CORONA, Statins, and Heart Failure: Who Lost the Crown?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Angiology.

CORONA, Statins, and Heart Failure: Who Lost the Crown?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008 .

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins Published, JLR Papers in Press, March 1, 2003. DOI 10.1194/jlr.M200452-JLR200

M. Elisaf, E. Bairaktari, A. Tambaki, 2003, Journal of Lipid Research.

Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.

E. Liberopoulos, M. Elisaf, G. Liamis, 2007, Archives of medical research.

Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.

G. Kolovou, D. Mikhailidis, T. Alexandrides, 2011, Current vascular pharmacology.

Combined Treatment with Fibrates and Small Doses of Atorvastatin in Patients with Mixed Hyperlipidemia

J. Goudevenos, M. Elisaf, G. Liamis, 2002, Current medical research and opinion.

Paralysis as first manifestation of primary aldosteronism.

C. Zamboulis, A. Karagiannis, K. Tziomalos, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effect of Atorvastatin on Serum Creatinine Levels

D. Mikhailidis, D. Mikhailidis, G. Liamis, 2001, Current medical research and opinion.

Fenofibrate induces HDL-associated PAF-acetylhydrolase but attenuates enzyme activity associated with apo B-containing lipoproteins

M. Elisaf, A. Tambaki, A. Tselepis, 2003 .

Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival

O. Giouleme, V. Papanikolaou, K. Tziomalos, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Fibrate treatment can increase serum creatinine levels

V. Tsimihodimos, A. Kakafika, M. Elisaf, 2001 .

Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism.

M. Florentin, A. Karagiannis, K. Tziomalos, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Statins and renal function. Is the compound and dose making a difference?

D. Mikhailidis, M. Elisaf, V. Athyros, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

High density lipoprotein cholesterol and statin trials.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Current medicinal chemistry.

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.

D. Mikhailidis, M. Elisaf, E. Bairaktari, 2004, Journal of cardiovascular pharmacology and therapeutics.

Statins and regression of coronary atherosclerosis.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2007, JAMA.

PO21-669 STATINS ON RENAL FUNCTION AND SERUM-URIC ACID AND THEIR RELATION TO VASCULAR EVENTS IN CORONARY HEART DISEASE AND METABOLIC SYNDROME

D. Mikhailidis, M. Elisaf, E. Liberopoulos, 2007 .

The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?

D. Mikhailidis, E. Liberopoulos, M. Elisaf, 2007, Expert opinion on therapeutic targets.

Hypouricemia in individuals admitted to an inpatient hospital-based facility.

M. Elisaf, E. Bairaktari, K. Seferiadis, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2007, Current pharmaceutical design.

Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin’s lymphoma

V. Perifanis, A. Karagiannis, P. Pateinakis, 2005, Annals of Hematology.

Has the time come for a new definition of microalbuminuria?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Current vascular pharmacology.

Liver function abnormalities in hyperlipidemic patients before and after hypolipidemic treatment

H. Milionis, M. Elisaf, D. Kiortsis, 2000 .

Coagulation, Platelets, and Acute Pancreatitis

D. Mikhailidis, K. Mimidis, A. Kakafika, 2007, Pancreas.

Targeting vascular risk in patients with metabolic syndrome but without diabetes.

D. Mikhailidis, M. Elisaf, V. Athyros, 2005, Metabolism: clinical and experimental.

Serum uric acid as an independent predictor of early death after acute stroke.

D. Mikhailidis, A. Karagiannis, T. Gossios, 2007, Circulation journal : official journal of the Japanese Circulation Society.

Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Endocrine-related cancer.

IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis

D. Mikhailidis, A. Papagianni, V. Athyros, 2011, Archives of medical science : AMS.

Effect of atorvastatin on serum uric acid levels.

V. Tsimihodimos, A. Kakafika, M. Elisaf, 2001, Atherosclerosis.

Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?

V. Athyros, A. Karagiannis, K. Tziomalos, 2009, Angiology.

Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values

D. Mikhailidis, M. Elisaf, E. Bairaktari, 2004 .

Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?

D. Mikhailidis, V. Athyros, A. Hatzitolios, 2007, Expert opinion on pharmacotherapy.

Do we need to consider inflammatory markers when we treat atherosclerotic disease?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Atherosclerosis.

Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study

Stella S. Daskalopoulou, Vasilios G. Athyros, S. Daskalopoulou, 2005, Platelets.

Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients

D. Mikhailidis, V. Athyros, A. Karagiannis, 2010, Neurological research.

SEASONAL VARIATION IN THE OCCURRENCE OF STROKE IN NORTHERN GREECE: A 10 YEAR STUDY IN 8,204 PATIENTS

D. Mikhailidis, A. Karagiannis, K. Tziomalos, 2008 .

Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

S. Daskalopoulou, A. Langer, D. Mikhailidis, 2004, Current medical research and opinion.

Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, Expert opinion on investigational drugs.

The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome

D. Mikhailidis, V. Athyros, A. Karagiannis, 2007, Journal of clinical pharmacology.

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study

A. Burroughs, D. Mikhailidis, E. Liberopoulos, 2006, Current medical research and opinion.

Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.

D. Mikhailidis, E. Liberopoulos, M. Elisaf, 2007, Current drug targets.

Targeting triglycerides in secondary prevention: should we bother?

D. Mikhailidis, A. Wierzbicki, D. Mikhailidis, 2009, International journal of clinical practice.

Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, American Journal of Cardiology.

Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?

D. Mikhailidis, V. Athyros, A. Karagiannis, 2009, Osteoporosis International.

Statins for the prevention of first or recurrent stroke.

V. Athyros, A. Karagiannis, K. Tziomalos, 2008, Current Vascular Pharmacology.

Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2008, The American journal of cardiology.

Fibrinogen: a predictor of vascular disease.

E. Liberopoulos, D. Mikhailidis, A. Kakafika, 2007, Current pharmaceutical design.

Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Fibrate treatment can increase serum creatinine levels.

V. Tsimihodimos, A. Kakafika, M. Elisaf, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The role of statins for the primary and secondary prevention of coronary heart disease in women.

D. Mikhailidis, V. Athyros, A. Karagiannis, 2009, Current pharmaceutical design.